CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 439 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,753,722 | -10.8% | 82,672 | +10.3% | 0.89% | -1.3% |
| Q2 2023 | $4,210,408 | -2.2% | 74,985 | -21.2% | 0.90% | -5.0% |
| Q1 2023 | $4,303,909 | +13.1% | 95,114 | +0.8% | 0.95% | +11.2% |
| Q4 2022 | $3,805,014 | -31.0% | 94,347 | +11.8% | 0.86% | -32.9% |
| Q3 2022 | $5,516,000 | +13.5% | 84,356 | +5.6% | 1.28% | +24.6% |
| Q2 2022 | $4,858,000 | +1.7% | 79,900 | +5.0% | 1.02% | +42.9% |
| Q1 2022 | $4,777,000 | – | 76,060 | – | 0.72% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |